Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

The Ministry of the Interior of Taiwan presented the 2023 Table of Life on Saturday indicating that the average life expectancy in the country would increase b ...

Exploring innovative therapies and market trends in lupus nephritis treatment, highlighting advancements in patient care and emerging drug developments.

The US FDA has imposed a clinical hold on Kezar Life Sciences’ IND application for zetomipzomib, aimed at treating lupus ...

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Kezar Life Sciences’ zetomipzomib, an ...

Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes. Nephrologists focus on renal preservation, while ...